Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
BASKING RIDGE, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results the second quarter ended June 30, 2024, on Monday, August 12, 2024, after the close of trading and will host a conference call at 4:30 p.m. Eastern time.
新澤西州巴斯金裏奇，2024年8月5日（環球新聞專線）——開發治療晚期實體瘤和其他嚴重疾病創新療法的臨床階段製藥公司Lisata Therapeutics, Inc.（納斯達克股票代碼：LSTA）（“Lisata” 或 “公司”）今天宣佈，該公司將於2024年8月12日星期一公佈截至2024年6月30日的第二季度財務業績。交易收盤後，並將於美國東部時間下午 4:30 舉行電話會議。
Those wishing to participate must register for the conference call by way of the following link: CLICK HERE TO REGISTER. Registered participants will receive an email containing conference call details with dial-in options. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time.
希望參加的人員必須通過以下鏈接註冊參加電話會議： 點擊這裏註冊。註冊的參與者將收到一封電子郵件，其中包含電話會議詳細信息和撥入選項。爲避免延遲，我們鼓勵參與者在預定開始時間前 15 分鐘撥入電話會議。
A live webcast of the call will also be accessible under the Investors & News section of Lisata's website and will be available for replay beginning two hours after the conclusion of the call for 12 months.
電話會議的網絡直播也將在以下網址下觀看 投資者與新聞 Lisata網站的部分，將在電話會議結束兩小時後開始重播，爲期12個月。
About Lisata Therapeutics
關於 Lisata Therapeu
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit .
Lisata Therapeutics 是 處於臨床階段的製藥公司 致力於發現、開發和商業化治療晚期實體瘤和其他主要疾病的創新療法。Lisata的候選產品certepide（前身爲 LSTA1）是一種在研藥物，旨在激活一種新的攝取途徑，該途徑允許共同給藥或聯用抗癌藥物更有效地選擇性靶向和穿透實體瘤。Lisata已經在其基礎上建立了值得注意的商業和研發合作伙伴關係 CendR 平台技術。該公司預計將在未來兩年內宣佈衆多里程碑，並相信其預計資本將爲2026年初的運營提供資金，其中包括正在進行和計劃中的臨床試驗的預期數據里程碑。有關該公司的更多信息，請訪問 。
Contact:
聯繫人：
Investors
投資者
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Lisata Therapeutics, In
約翰·門迪託
投資者關係和企業傳播副總裁
電話：908-842-0084
電子郵件：jmenditto@lisata.com
Media:
媒體：
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
ICR Westwicke
伊麗莎白·科爾曼
高級助理
電話：203-682-4783
電子郵件：elizabeth.coleman@westwicke.com